A study to assess the safety, tolerability and anti-tumour activity of ascending doses of selumetinib in combination with MEDI4736 and Selumetinib in Combination with MEDI4736 and Tremelimumab in patients with advanced solid tumours

Trial Identifier: D1345C00003
Sponsor: AstraZeneca
NCTID:: NCT02586987
Start Date: December 2015
Primary Completion Date: July 2018
Study Completion Date: September 2019
Condition: Liver Cancer; Breast Cancer; Colorectal Cancer; Esophageal cancer; Cancer - Other; Lung Cancer; Skin Cancer; Pancreatic Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version

Trial Locations

Country Location
United States of America, IL Chicago, IL, United States of America, 60637
United States of America, MA Boston, MA, United States of America, 02215
United States of America, NC Charlotte, NC, United States of America, 28204
United States of America, Nevada Las Vegas, Nevada, United States of America, 89169-3321
United States of America, NJ New Brunswick, NJ, United States of America, 08901
United States of America, PA Pittsburgh, PA, United States of America, 15232